Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
Part of paid clinical trials in Miami, Florida.
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Study ID
- NCT04716946
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
- Lung Cancer
- NSCLC
- Non-small Cell Lung Cancer
- Non-small Cell Lung Cancer Stage I
- Non-small Cell Lung Cancer Stage II
- Non-small Cell Lung Cancer Stage III
- Non-small Cell Lung Cancer Stage IIIA
- PD-L1 Gene Mutation
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Durvalumab — DRUGPatients will receive durvalumab 1500mg durvalumab via IV infusion over 1 hour, once every 4 weeks (Q4W) for up to a maximum of 6 months (up to 6 doses/cycles) unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.
- Stereotactic Body Radiation Therapy — RADIATIONRadiation therapy will be performed with external beam ionizing radiation in accordance with institutional standard practice. 3D conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT) or volumetric arc therapy (VMAT) will be used at the discretion of the treating radiation oncologist.
Study Details
The purpose of this study is to find out whether treatment with the study drug durvalumab combined with a type of radiation therapy called stereotactic body radiation (SBRT) is a more effective treatment for early-stage non-small cell lung cancer (NSCLC) than SBRT alone.
Key Dates
- Start date
- Jan 27, 2021
- Status verified
- May 2026
- Primary completion
- Feb 28, 2027
- Completion
- Feb 28, 2027
Study Design
- Enrollment
- 13 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Participants with Early-stage Non-Small Cell Lung CancerParticipants will be diagnosed with Stage I-IIIA NSCLC and will be ineligible for surgery and will have any level of PD-L1
Primary Outcome Measure
Progression Free Survival [ Time Frame: 2 years ]
Locations (8)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Baptist Alliance - McI | Miami | Florida | 33143 | - |
| Memorial Sloan Kettering Basking Ridge | Basking Ridge | New Jersey | 07920 | - |
| Memorial Sloan Kettering Monmouth | Middletown | New Jersey | 07748 | - |
| Memorial Sloan Kettering Bergen | Montvale | New Jersey | 07645 | - |
| Memorial Sloan Kettering Cancer Center @ Suffolk - Commack | Commack | New York | 11725 | - |
| Memorial Sloan Kettering Westchester | Harrison | New York | 10604 | - |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | - |
| Memorial Sloan Kettering Nassau | Rockville Centre | New York | 11553 | - |
Find similar trials in Miami, FL
By condition
By specialty
By research site
Baptist Alliance - McI· Miami, FLMemorial Sloan Kettering Basking Ridge· Basking Ridge, NJMemorial Sloan Kettering Monmouth· Middletown, NJMemorial Sloan Kettering Bergen· Montvale, NJMemorial Sloan Kettering Cancer Center @ Suffolk - Commack· Commack, NYMemorial Sloan Kettering Westchester· Harrison, NY
Related Studies
- Lung Cancer Biomarkers and ScreeningRecruiting · NYU Langone Health · New York, New York
- Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL ActivityPHASE2 · Recruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung CancerPHASE3 · Recruiting · University of Texas Southwestern Medical Center · La Jolla, California